Rexin-G was well tolerated and there was no dose-limiting toxicity. At dose level I, three patients achieved stable disease with no tumor progression; and at dose level II, one patient had a 37% decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.
Importantly, Rexin-G improved patient survival in a dose-dependent manner: At dose level I, median progression-free survival was three months, and median over-all survival was five months, while at dose level II, median progression-free survival was greater than three months, and median over-all survival was greater than nine months, the company said.
According to the company, the present study confirms the overall safety of Rexin-G, and further demonstrates that Rexin-G monotherapy, at these defined dose levels, exhibits profound anti-tumor activity that prolongs both progression-free survival and over-all survival time in pancreatic cancer patients that had previously failed standard chemotherapy.
The company claims Rexin-G to be the world’s first and so far only targeted injectable genetic medicine that has been validated in the clinic. Injected intravenously, the targeted nanoparticles are designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.